Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

4.3K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
4.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lactate dehydrogenase (LDH) as a predictor of left atrial remodeling in patients with sickle cell anemia.

Annals of hematology·2026
Same author

Evaluating the treatment of patients with paroxysmal nocturnal hemoglobinuria in Brazil: disparities in access and treatment persistence.

Hematology, transfusion and cell therapy·2026
Same author

Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025).

Hematology, transfusion and cell therapy·2026
Same author

Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial.

Hematological oncology·2025
Same author

Integrated Genomic and Transcriptomic Profiling of Isolated Trisomies in AML Reveals Cell Cycle Dysregulation and Therapeutic Vulnerabilities.

Journal of cellular and molecular medicine·2025
Same author

Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia.

Cytometry. Part B, Clinical cytometry·2025

Related Experiment Video

Updated: Mar 16, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K

Primary myelofibrosis: current therapeutic options.

Paula de Melo Campos1

  • 1Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil.

Revista Brasileira De Hematologia E Hemoterapia
|August 14, 2016
PubMed
Summary

Primary myelofibrosis, a bone marrow disorder, involves fibrosis and can lead to acute myeloid leukemia. Current treatments focus on disease modification and palliative care for improved quality of life.

Keywords:
Janus kinase 2Myeloproliferative disordersPrimary myelofibrosis

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

893
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.1K

Related Experiment Videos

Last Updated: Mar 16, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

893
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.1K

Area of Science:

  • Hematology
  • Oncology

Background:

  • Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm.
  • Characterized by bone marrow fibrosis, clonal myeloid expansion, and potential transformation to acute myeloid leukemia.
  • Patients often experience constitutional symptoms and hepatosplenomegaly, significantly impacting quality of life.

Purpose of the Study:

  • To discuss current treatment options for primary myelofibrosis.
  • To consider both disease-modifying therapeutics and palliative measures.
  • To emphasize an individualized, patient-based approach to treatment.

Main Methods:

  • Review of current therapeutic strategies for primary myelofibrosis.
  • Discussion of disease-modifying agents.
  • Consideration of palliative care interventions.

Main Results:

  • Treatment approaches vary based on individual patient needs.
  • Disease-modifying therapies aim to alter the disease course.
  • Palliative measures address symptom burden and improve quality of life.

Conclusions:

  • Management of primary myelofibrosis requires a personalized strategy.
  • A combination of disease-modifying and palliative treatments is often necessary.
  • Individualized care is crucial for optimizing outcomes in primary myelofibrosis patients.